In a study, blocking the immune system complement protein C3 was shown to reduce MS disease severity in older mice but not in ...

SÃO PAULO--(BUSINESS WIRE)--Pint Pharma and OrphanDC announced on July 25th that ANVISA, the National Health Surveillance Agency, approved, on July 25th, 2023, the drug EMPAVELI® (pegcetacoplan, ...

Opportunities in the C5 inhibitors market include developing next-gen biosimilars and biosuperiors to improve administration frequency and expand treatment indications for diseases like aHUS, SCD, MG, ...

Complement 3 glomerulopathy (C3G) is considered a very rare disease. With C3G, patients have issues with their immune system that cause kidney damage and symptoms such as swelling and changes in urine ...